0001493152-23-020350.txt : 20230607 0001493152-23-020350.hdr.sgml : 20230607 20230607080023 ACCESSION NUMBER: 0001493152-23-020350 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230607 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230607 DATE AS OF CHANGE: 20230607 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Enveric Biosciences, Inc. CENTRAL INDEX KEY: 0000890821 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 954484725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38286 FILM NUMBER: 23997685 BUSINESS ADDRESS: STREET 1: 4851 TAMIAMI TRAIL N, SUITE 200 CITY: NAPLES STATE: FL ZIP: 34103 BUSINESS PHONE: 239-302-1707 MAIL ADDRESS: STREET 1: 4851 TAMIAMI TRAIL N, SUITE 200 CITY: NAPLES STATE: FL ZIP: 34103 FORMER COMPANY: FORMER CONFORMED NAME: AMERI Holdings, Inc. DATE OF NAME CHANGE: 20150527 FORMER COMPANY: FORMER CONFORMED NAME: SPATIALIZER AUDIO LABORATORIES INC DATE OF NAME CHANGE: 19950323 8-K 1 form8-k.htm
0000890821 false 0000890821 2023-06-07 2023-06-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

June 7, 2023

Date of Report (Date of earliest event reported)

 

Enveric Biosciences, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38286   95-4484725

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

Enveric Biosciences, Inc.

4851 Tamiami Trail N, Suite 200

Naples, FL 34103

(Address of principal executive offices) (Zip code)

 

Registrant’s telephone number, including area code: (239) 302-1707

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.01 per share   ENVB   The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On June 7, 2023, Enveric Biosciences, Inc. (the “Company”) issued a press release announcing that the Company’s research involving the synthesis of small molecule derivatives of psychoactive compounds has been featured in two poster presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023) being held in Vancouver June 4-8, 2023. A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit

Number

   Description
   
99.1   Press Release, dated June 7, 2023 (furnished pursuant to Item 7.01)
104   Cover Page Interactive Data File (formatted as Inline XBRL)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 7, 2023 ENVERIC BIOSCIENCES, INC.
     
  By: /s/ Joseph Tucker
    Joseph Tucker
    Chief Executive Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)

 

CAMBRIDGE, Mass., June 7, 2023 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that its research involving the synthesis of small molecule derivatives of psychoactive compounds has been featured in two poster presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023) being held in Vancouver June 4-8, 2023.

 

The first poster titled, “Novel psilocin prodrugs with altered pharmacological properties as candidate therapies for treatment-resistant anxiety disorders,” describes the chemical synthesis of Enveric’s EVM201 Series molecules to identify novel prodrugs of psilocin with altered metabolic profiles and reduced pharmacological exposure aimed at reducing the duration of the psychedelic experience. Beginning with 30 unique molecules, representing nine distinct prodrug classes, 15 candidates were selected that released the highest levels of psilocin in vitro. Pharmacokinetic analysis confirmed that the efficient release of psilocin in vitro correlated with the amount of psilocin detected in blood plasma. Two molecules that produced plasma psilocin concentrations comparable or superior to psilocybin were evaluated for long-term anxiolytic benefit in chronically stressed mice using the marble-burying psychiatric model.

 

The second poster titled, “Design, synthesis and pharmacological evaluation of novel MDMA derivatives as potential therapies for the treatment of psychiatric conditions,” describes the design and chemical synthesis of a library of 30 novel MDMA (Ecstasy) derivatives. The compounds were tested for their ability to bind serotonin receptors and transporters. The results show how modifications to the chemical structure of MDMA can lead to substantial alteration in binding to different serotonin receptors and transporters, which could alter pharmacological properties.

 

“The two posters presented at CSC 2023 showcase the pioneering work of our researchers and collaborators, who are using cutting-edge techniques to produce novel therapeutic candidates that harness key properties of known psychoactive compounds but are designed to display safer pharmacologic profiles more applicable in the mental health setting,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “We are proud to see the work of our research teams presented at this prestigious scientific conference, and we look forward to their continued contributions to this important field, which we feel has the potential to generate new and improved treatments for people living with mental health conditions.”

 

 

 

 

Details of the poster presentations are as follows:

 

Title: Novel psilocin prodrugs with altered pharmacological properties as candidate therapies for treatment-resistant anxiety disorders

 

Presenter: Sheetal A. Raithatha, Enveric Biosciences

 

Authors: Sheetal A. Raithatha, Jill M. Hagel, Kaveh Matinkhoo, Lisa Yu, David Press, Govinda Sharma, Dhananjaya D., Sarah G. Cook, Glynnis Jensen, Jessica Lee, Charlie Cai, Jonathan Gallant, Stanley Opare, Xue Chen, Jing Li, Limei Chang, Francesca Maule, Joseph E. Tucker, Peter J. Facchini

 

Title: Design, synthesis and pharmacological evaluation of novel MDMA derivatives as potential therapies for the treatment of psychiatric conditions

 

Presenter: Kaveh Matinkhoo, Enveric Biosciences

 

Authors: Kaveh Matinkhoo, Jill M. Hagel, Sheetal A. Raithatha, David Press, Glynnis Jensen, Jessica Lee, Charlie Cai, Lisa Yu, Govinda Sharma, Dhananjaya D., Sarah G. Cook, Jonathan Gallant, Stanley Opare, Xue Chen, Jing Li, Limei Chang, Francesca Maule, Joseph E. Tucker, Peter J. Facchini

 

About Enveric Biosciences

 

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Leveraging its unique discovery and development platform, The Psybrary™, Enveric has created a robust Intellectual Property portfolio of New Chemical Entities for specific mental health indications. Enveric’s lead program, the EVM201 Series, comprises next generation synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series – EB-373 – for the treatment of anxiety disorders. Enveric is also advancing its second program, the EVM301 Series, to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com.

 

 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” expects” or “does not expect,” “proposed,” “is expected,” “budgets,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements may include historical statements and statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: carry out successful clinical programs in Australia; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its cannabinoid clinical development pipeline assets; continue as a going concern; manage its future growth effectively; transition from third-party service providers supporting R&D efforts to internal science teams without any adverse impact on Enveric’s ongoing and planned clinical trials; and achieve the intended benefits of its cost reduction plan efforts without negatively impacting Enveric’s business operations and reputation.

 

A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission (SEC), including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

Contact

 

Investor Relations

Tiberend Strategic Advisors, Inc.

Daniel Kontoh-Boateng

(862) 213-1398

dboateng@tiberend.com

 

Media Relations

Tiberend Strategic Advisors, Inc.

Casey McDonald

(646) 577-8520

cmcdonald@tiberend.com

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 envb-20230607.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 envb-20230607_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 envb-20230607_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Jun. 07, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 07, 2023
Entity File Number 001-38286
Entity Registrant Name Enveric Biosciences, Inc.
Entity Central Index Key 0000890821
Entity Tax Identification Number 95-4484725
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One Enveric Biosciences, Inc.
Entity Address, Address Line Two 4851 Tamiami Trail N
Entity Address, Address Line Three Suite 200
Entity Address, City or Town Naples
Entity Address, State or Province FL
Entity Address, Postal Zip Code 34103
City Area Code (239)
Local Phone Number 302-1707
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.01 per share
Trading Symbol ENVB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000890821 2023-06-07 2023-06-07 iso4217:USD shares iso4217:USD shares 0000890821 false 8-K 2023-06-07 Enveric Biosciences, Inc. DE 001-38286 95-4484725 Enveric Biosciences, Inc. 4851 Tamiami Trail N Suite 200 Naples FL 34103 (239) 302-1707 false false false false Common stock, par value $0.01 per share ENVB NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://enveric.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm envb-20230607.xsd envb-20230607_lab.xml envb-20230607_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "envb-20230607_lab.xml" ] }, "presentationLink": { "local": [ "envb-20230607_pre.xml" ] }, "schema": { "local": [ "envb-20230607.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ENVB", "nsuri": "http://enveric.com/20230607", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-06-07to2023-06-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://enveric.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-06-07to2023-06-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enveric.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-020350-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-020350-xbrl.zip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end